Tempest Therapeutics, Inc. (TPST) — SEC Filings
Tempest Therapeutics, Inc. (TPST) — 41 SEC filings. Latest: 8-K (May 6, 2026). Includes 15 8-K, 6 10-Q, 3 10-K.
View Tempest Therapeutics, Inc. on SEC EDGAR
Overview
Tempest Therapeutics, Inc. (TPST) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 424B3 filed on Apr 10, 2026: Tempest Therapeutics, Inc. filed a 424B3 prospectus on April 10, 2026, detailing its securities offering. The filing provides information for investors regarding the company's offerings, with its principal executive offices located at 2000 Sierra Point Parkway, Suite 400, Brisbane, CA 94005.
Sentiment Summary
Across 41 filings, the sentiment breakdown is: 1 bullish, 4 bearish, 33 neutral, 3 mixed. The dominant filing sentiment for Tempest Therapeutics, Inc. is neutral.
Filing Type Overview
Tempest Therapeutics, Inc. (TPST) has filed 15 8-K, 2 424B3, 2 EFFECT, 1 S, 3 10-K, 3 DEF 14A, 1 S-1, 1 DEFA14A, 6 10-Q, 1 10-K/A, 3 SC 13D/A, 3 SC 13G/A with the SEC between Feb 2024 to May 2026.
Filings by Year
Recent SEC Filings (41)
Risk Profile
Risk Assessment: Of TPST's 37 recent filings, 5 were flagged as high-risk, 23 as medium-risk, and 9 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | $-103.9M |
| EPS | $-2.91 |
| Debt-to-Equity | 0.0 |
| Cash Position | $10.7M |
| Operating Margin | N/A |
| Total Assets | $37.7M |
| Total Debt | $0 |
Key Executives
- Geoff Nichol
- Nicholas Maestas
- Stephen Brady
- Samuel Whiting
- Michael Raab
- Ronit Simantov
- Abigail P. Johnson
- Max Eisenberg
Industry Context
The biotechnology industry, particularly in oncology, is characterized by rapid innovation and significant investment in novel therapeutic modalities like CAR-T and small molecule inhibitors. Companies are increasingly focused on dual-targeting strategies and capital-efficient development through partnerships and external funding. The competitive landscape is intense, with numerous players vying for breakthroughs in areas of high unmet medical need, such as relapsed/refractory multiple myeloma and hepatocellular carcinoma.
Top Tags
filing (5) · Biotechnology (5) · sec-filing (4) · Oncology (4) · corporate-action (4) · 10-Q (4) · financials (4) · amendment (4) · pharmaceuticals (3) · prospectus (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Form Type | 424B3 | Indicates a prospectus filing for securities offerings |
| Accession Number | 0001193125-26-150470 | Unique identifier for the SEC filing |
| SEC Accession Number | 0001193125-26-150469 | Unique identifier for this specific SEC filing |
| File Number | 333-294740 | Associated file number for the registration statement |
| CIK | 0001544227 | Tempest Therapeutics' unique identifier with the SEC. |
| Market Value of Non-Affiliate Equity | $30.1M | As of June 30, 2025, indicating a smaller market capitalization. |
| Shares Issued for Acquisition | 8.27M | Represents significant dilution for existing shareholders due to the Asset Acquisition. |
| Improvement in Median Overall Survival | 6 months | Achieved by amezalpat in Phase 2 HCC study, a key positive clinical outcome. |
| Hazard Ratio for OS | 0.65 | Demonstrated by amezalpat in Phase 2 HCC study, indicating a reduced risk of death. |
| Expected Phase 2 Initiation for TPST-1495 | 2026 | Marks a key clinical milestone for the small-molecule pipeline, funded by NCI. |
| Anticipated Registrational Phase 2b Initiation for TPST-2003 in China | 2026 | A critical step towards potential market approval for the lead CAR-T candidate. |
| Shares of common stock to be issued | 8,268,495 | In satisfaction of obligations under an asset purchase agreement, significantly diluting existing shares. |
| Shares of common stock outstanding | 4,927,161 | As of the Record Date (December 4, 2025), indicating substantial potential dilution from the proposed issuance. |
| Additional shares for Equity Incentive Plan | 1,410,000 | Proposed increase to the Amended and Restated 2023 Equity Incentive Plan, further contributing to potential dilution. |
| Annual Meeting Date | January 27, 2026 | Date when stockholders will vote on key proposals. |
Forward-Looking Statements
- {"claim":"Tempest Therapeutics' stock price may experience downward pressure due to the reduced institutional ownership.","entity":"Tempest Therapeutics, Inc.","targetDate":"Q1 2024","confidence":"medium"}
- {"claim":"Versant Venture Capital VI, L.P. will continue to be a significant institutional holder in Tempest Therapeutics, Inc.","entity":"Versant Venture Capital VI, L.P.","targetDate":"2025-02-08","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Tempest Therapeutics, Inc. (TPST)?
Tempest Therapeutics, Inc. has 41 recent SEC filings from Feb 2024 to May 2026, including 15 8-K, 6 10-Q, 3 10-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of TPST filings?
Across 41 filings, the sentiment breakdown is: 1 bullish, 4 bearish, 33 neutral, 3 mixed. The dominant sentiment is neutral.
Where can I find Tempest Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Tempest Therapeutics, Inc. (TPST) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Tempest Therapeutics, Inc.?
Key financial highlights from Tempest Therapeutics, Inc.'s most recent 10-K include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for TPST?
The investment thesis for TPST includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Tempest Therapeutics, Inc.?
Key executives identified across Tempest Therapeutics, Inc.'s filings include Geoff Nichol, Nicholas Maestas, Stephen Brady, Samuel Whiting, Michael Raab and 3 others.
What are the main risk factors for Tempest Therapeutics, Inc. stock?
Of TPST's 37 assessed filings, 5 were flagged high-risk, 23 medium-risk, and 9 low-risk.
What are recent predictions and forward guidance from Tempest Therapeutics, Inc.?
Recent forward-looking statements from Tempest Therapeutics, Inc. include guidance on {"claim":"Tempest Therapeutics' stock price may experience downward pressure due to the reduced institutional ownership. and 1 other predictions.